Table 1.
Baseline characteristics of AML patients treated with GO 3 mg/m(2) during reinduction and consolidation phases based on CD33 rs12459419 polymorphism.
| CD33 rs12459419 genotype in AML patients treated with GO in reinduction and consolidation phases | ||||||
|---|---|---|---|---|---|---|
| Reinduction treatment | Consolidation treatment | |||||
| Patients characteristics | Total; n =20 | CC (n = 12; 60%) | CT/TT (n = 7/1; 35%/5%) | Total; n = 70 | CC (n = 32; 46%) | CT/TT (n = 34/4; 49%/6%) |
| Median age at diagnosis, years | 51 | 49.5 | 53.9 | 57.2 | 57.2 | 57.7 |
| Range | 17.4–64.2 | 17.4-64.1 | 30.4-61.2 | 24.8–76.9 | 24.8-70.0 | 28.2-76.9 |
| Median follow-up, years | 0.58 | 0.58 | 0.25 | 2.13 | 1.96 | 2.17 |
| Sex | ||||||
| Female | 10 (50%) | 8 (67%) | 2 (25%) | 36 (51%) | 18 (56%) | 18 (47%) |
| Male | 10 (10%) | 4 (33%) | 6 (75%) | 34 (49%) | 14 (44%) | 20 (53%) |
| Cytogenetic risk (ELN 2010) | ||||||
| Favorable risk | 5 (25%) | 4 (33%) | 1 (13%) | 28 (40%) | 15 (47%) | 13 (34%) |
| Intermediate-I risk | 2 (10%) | 2 (17%) | ─ | 20 (29%) | 8 (25%) | 12 (32%) |
| Intermediate-II risk | 6 (30%) | 3 (25%) | 3 (38%) | 7 (10%) | 3 (9%) | 4 (11%) |
| Adverse risk | 6 (30%) | 3 (25%) | 3 (38%) | 9 (13%) | 4 (13%) | 5 (13%) |
| Median leucocytes at diagnosis, 109/L | 14.7 | 16.0 | 22.8 | 17.5 | 17.5 | 17.5 |
| Range | 1.6-206.6 | 1.6-100.5 | 1.9-206.6 | 0,7-379 | 1,1-379 | 0,7-324 |
| Median hemoglobin at diagnosis, g/dl | 8.7 | 8.7 | 8.8 | 9.5 | 9,5 | 9,5 |
| Range | 4.6-11.2 | 4.6-11.2 | 5.5-10.9 | 5-13,9 | 5-13,9 | 5,3-13,5 |
| Median platelets at diagnosis, 109/L | 53 | 53 | 49 | 65 | 65 | 62 |
| Range | 15-261 | 30-261 | 15-97 | 14-336 | 14-317 | 13-336 |
| Treatment | ||||||
| Induction therapy | ||||||
| Idarubicin+cytarabine (3 + 7) | 19 (95%) | 11 (92%) | 8 (100%) | 59 (84%) | 27 (84%) | 32 (84%) |
| Idarubicin+cytarabine (2 + 5) | 1 (5%) | 1 (8%) | ─ | 9 (13%) | 5 (16%) | 4 (11%) |
| Other treatments | ─ | ─ | ─ | 2 (3%) | ─ | 2 (5%%) |
| Reinduction | ||||||
| 3 + 7 with GO | 1 (5%) | ─ | 1 (12.5%) | ─ | ─ | ─ |
| IDA-FLAGO | 19 (95%) | 12 (100%) | 7 (87.5%) | ─ | ─ | ─ |
| Other treatments | ─ | ─ | ─ | ─ | ─ | ─ |
| Consolidation | ||||||
| HDARAC+GO | ─ | ─ | ─ | 14 (20%) | 6 (19%) | 8 (21%) |
| 3 + 7 + GO | ─ | ─ | ─ | 56 (80%) | 26 (81%) | 30 (79%) |
| HDARAC | 6 (30%) | 4 (33%) | 2 (25%) | ─ | ─ | |
| IDA-FLAG | 2 (10%) | 2 (17%) | ─ | ─ | ─ | |
| Support treatment | 1 (5%) | 1 (8%) | ─ | ─ | ─ | |
| Stem cell transplant | ||||||
| Allogeneic hematopoietic cell transplantation | 11 (55%) | 8 (67%) | 3 (38%) | 22 (31%) | 11 (34%) | 11 (29%) |
| Autologous hematopoietic cell transplantation | ─ | ─ | ─ | 19 (27%) | 6 (19%) | 13 (29%) |
Abbreviations: GO: gemtuzumab ozogamicin; ELN: European Leukemia Net; IDA-FLAG/IDA-FLAGO: idarubicin, fludarabine, cytarabine, and G-CSF ± GO; ARAC (100 mg/m2 during 5 days); HDARAC (1-3 g/m2 during 1, 3, and 5 days of the cycle).